Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05400811
Other study ID # MM09-SIT-040
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date December 2022
Est. completion date July 2025

Study information

Verified date April 2022
Source Inmunotek S.L.
Contact Miguel Casanovas, MD, PhD
Phone 912908942
Email mcasanovas@inmunotek.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and rhinitis/rhinoconjunctivitis (intermittent or persistent) allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae.


Description:

Prospective multicenter randomized double-dummy clinical trial of three active treatment groups compared to one placebo group. The principal objective of the clinical trial is the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and rhinitis/rhinoconjunctivitis (intermittent or persistent) allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. The primary efficacy endpoint will be the symptom score and medication consumption required for the control of asthma and rhinitis/rhinoconjunctivitis symptoms. The study design consists of 3 active treatment groups and one placebo group. The trial population will include 400 subjects between the age of 12 and 60 years that will receive the treatment during 12 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 400
Est. completion date July 2025
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years to 60 Years
Eligibility Inclusion Criteria: 1. Signed and dated Informed Consent Form (ICF). 2. Female or male aged 12 to 60 years, both included. 3. Confirmed clinical history of inhalation allergy (mild-moderate controlled intermittent or persistent asthma according to the definition of GEMA 5.0 and GINA 2020 and intermittent or persistent rhinitis / rhinoconjunctivitis according to the ARIA classification, caused by Dermatophagoides pteronyssinus and / or Dermatophagoides farinae). The asthma diagnosis will be valid up to 24 months prior to signing the informed consent. 4. Positive skin prick test (wheal major diameter = 5 mm) to a standardized allergen extract of Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. 5. Specific IgE against a complete extract of D. pteronyssinus and/or D. farinae or any of the molecular components of allergenic sources with a value = 3.5 kU/L. 6. Women of childbearing age must have a urine pregnancy test negative result before enrolling the study. 7. Women of childbearing age must commit to using an adequate contraception method. 8. Capable of complying with dosage regimen. 9. Owning a smartphone to register symptoms and medication consumption. 10. A negative skin prick test to other aeroallergens with specific IgE < 3.5 kU/L with no clinical relevance. Exclusion Criteria: 1. Previous immunotherapy to any of the tested allergen during the last 5 years or any desensitization process in the last 2 years (ITO, milk, egg, ...) or currently receiving immunotherapy with any other allergen. 2. Positive skin prick test to other aeroallergens, except for intermittent symptoms due to temporary exposition to dander. 3. Those cases in which AIT would be a contraindication according to the criteria of European Allergy and Clinical Immunology Immunotherapy Subcommittee. 4. Uncontrolled or severe asthma and/or FEV1 <70% despite pharmacological treatment by the time of enrolment. 5. Intake of ß-blockers. 6. Use of immunosuppressive or biological drug. 7. Unstable patients by the time of enrolment (acute exacerbation asthma, respiratory infection, fever, acute pruritus, etc). 8. Patients who have suffered chronic urticaria during the last 2 years, severe anaphylaxis, or family history of angioedema. 9. Having any contraindication for the use of adrenaline (hyperthyroidism, heart disease, high blood pressure). 10. Other severe diseases not related to allergic asthma or rhinitis that could interfere in the study treatment or the follow-up (epilepsy, psychomotor agitation, diabetes, malformations, nephropathy) according to medical criteria. 11. Autoimmune diseases (thyroiditis, lupus, etc.), tumoral diseases or immunodeficiencies. 12. Participants that the investigator believes could not comply with the study protocol or have serious psychiatric disorders. 13. Known allergy to any of the ingredients of the study medication except for mites. 14. Lower respiratory tract diseases different from asthma as bronchiectasis or chronic obstructive pulmonary disease. 15. Breast-feeding or pregnant women. 16. Being immediate family of the investigator. 17. Concurrent participation in other clinical trials or prior participation within 30 days prior to inclusion. 18. History of serious systemic reactions, including food, Hymenoptera venom, medications, etc.

Study Design


Intervention

Biological:
MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL)
Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for subcutaneous administration.
MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL)
Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 3.000 UTm/mL for sublingual administration.
MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)
Mixture of allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae conjugated to mannan at 9.000 UTm/mL for sublingual administration.
Placebo subcutaneous
The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
Placebo sublingual
The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.

Locations

Country Name City State
Spain Hospital Universitario A Coruña A Coruña
Spain Centro Médico Quiron Salud Alicante Alicante
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital Universitario de Elche Elche Alicante
Spain Hospital Sant Joan de Déu Esplugues De Llobregat Barcelona
Spain Policlínica Nuestra Sra del Rosario Ibiza Baleares
Spain Clinica del Dr.Pérez Estrada Cornejo Málaga
Spain Hopital Quirón Salud Málaga Málaga
Spain Hospital Universitario Regional de Málaga Málaga
Spain Clínica RUSADIR Melilla
Spain Hospital Universitario de Navarra Pamplona Navarra
Spain Complexo Hospitalario Universitario de Pontevedra Pontevedra
Spain Hospital Universitario de Canarias San Cristóbal de La Laguna Santa Cruz De Tenerife
Spain Hospital de Terrassa Terrassa Barcelona
Spain Hospital Univeristario y Politécnico La Fe Valencia
Spain Hospital Universitario de la Plana Vila-real

Sponsors (3)

Lead Sponsor Collaborator
Inmunotek S.L. BioClever 2005 S.L., NTS hub S.L

Country where clinical trial is conducted

Spain, 

References & Publications (6)

Benito-Villalvilla C, Soria I, Subiza JL, Palomares O. Novel vaccines targeting dendritic cells by coupling allergoids to mannan. Allergo J Int. 2018;27(8):256-262. doi: 10.1007/s40629-018-0069-8. Epub 2018 May 18. Review. — View Citation

González JL, Zalve V, Fernández-Caldas E, Cases B, Subiza JL, Casanovas M. A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan-Dermatophagoides farinae allergoid targeting dendritic cells. Vet Dermatol. 2018 Oct;29(5):449-e152. doi: 10.1111/vde.12679. — View Citation

Manzano AI, Javier Cañada F, Cases B, Sirvent S, Soria I, Palomares O, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Subiza JL. Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Glycoconj J. 2016 Feb;33(1):93-101. doi: 10.1007/s10719-015-9640-4. Epub 2015 Nov 25. — View Citation

Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, Reche PA, López-Relaño J, Martínez-Naves E, Cañada FJ, Jiménez-Barbero J, Subiza J, Casanovas M, Fernández-Caldas E, Subiza JL, Palomares O. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11. doi: 10.1016/j.jaci.2016.02.029. Epub 2016 Apr 13. — View Citation

Soria I, Alvarez J, Manzano AI, López-Relaño J, Cases B, Mas-Fontao A, Cañada FJ, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Palomares O, Viñals-Flórez LM, Subiza JL. Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. Vet Immunol Immunopathol. 2017 Aug;190:65-72. doi: 10.1016/j.vetimm.2017.07.004. Epub 2017 Jul 23. — View Citation

Soria I, López-Relaño J, Viñuela M, Tudela JI, Angelina A, Benito-Villalvilla C, Díez-Rivero CM, Cases B, Manzano AI, Fernández-Caldas E, Casanovas M, Palomares O, Subiza JL. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. Allergy. 2018 Apr;73(4):875-884. doi: 10.1111/all.13396. Epub 2018 Jan 31. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary CSMS: Combined Symptoms and Medication Score Evaluation of the number of symptoms and the consumption of medication necessary for the control of such symptoms in asthma and rhinitis / rhinoconjunctivitis of each subject during the trial, of the groups with each other and with respect to placebo.
- The endpoint for each asthma and rhinitis / rhinoconjunctivitis symptom will be as follows: 0 = No symptoms; 1 = Mild; 2 = Moderate; 3 = Severe
Total daily symptom score = 0-3
The asthma medication will be scored based on the therapeutic step in which drugs are included in the GEMA 5 guide.
The rhinitis / rhinoconjunctivitis medication score: 0 = No medication; 1 = oral or topical (eyes or nose) non-sedative H1 antihistamines (H1A); 2 = intranasal corticosteroids (INS) with / without H1A; 3 = oral corticosteroids with/without (INS), with/without H1A Total daily medication score = 0-3
12 months
Secondary Asthma symptom-free days Number of days that subjects have no symptoms related to asthma 12 months
Secondary Rhinitis / rhinoconjunctivitis symptom-free days Number of days that subjects have no symptom related to rhinitis / rhinoconjunctivitis. 12 months
Secondary Asthma medication-free days Number of days that subjects need no medication for treatment of asthma. 12 months
Secondary Rhinitis / rhinoconjunctivitis medication-free days Number of days that subjects need no medication for treatment of Rhinitis / rhinoconjunctivitis. 12 months
Secondary Respiratory function_FEV1 Measurement of Forced Expiratory Volume in 1 Second (FEV1) % Baseline, month 6, month 12
Secondary Respiratory function_PEF Peak Expiratory Flow (PEF) [velocity] Baseline, month 6, month 12
Secondary Asthmatic exacerbations Time elapsed until the first appearance of asthmatic exacerbations, number, duration and severity. 12 months
Secondary Clinical benefit Time to onset of clinical benefit 12 months
Secondary Immunological parameters Analyses of total and specific IgE, specific IgE index / total IgE, specific IgG4 and Anti-Saccharomyces cerevisiae (ASCA) IgA&IgG. 12 months
Secondary Quality of life associated with asthma (AQLQ) The quality of life associated with asthma will be measured using the Asthma Quality of Life Questionnaire (AQLQ).
AQLQ consists of 32 items and 4 domains (limitations in activities, symptoms, emotional and environmental). Each item is scored from 1=no impairment to 7=severe impairment.
12 months
Secondary Quality of life associated with rhinoconjunctivitis (RQLQ) The quality of life associated with rhinoconjunctivitis will be measured using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).
RQLQ it consists of 28 items (questions) and 7 domains (Activities, sleep, general symptoms, practical problems, nose symptoms, eye and emotional symptoms).
The score of each item for all domains, except for the emotional one, ranges from "0=Nothing bothered me" to "6=It has bothered me a lot". The emotional domain score ranges from "0=Never" to "6=Always".
Baseline, month 6, month 12
Secondary Questionnaire for asthma control (ACQ) Asthma control will be measured following the ACQ questionnaire.
The ACQ questionnaire consists of 7 questions (ACQ-7) or 6 questions (ACQ-6). In questions 1-6, patients recall their experience during the last 7 days and answer using a scale of 7 points (from "0 = fully controlled" to "6 = extremely poorly controlled"). The seventh question, which refers to the% FEV1 of the reference value, must be completed by an employee of the site. The questionnaire score is the mean of the 7 responses (ACQ-7) or 6 responses (ACQ-6).
The interpretation of the scores is as follows:
Less than or equal to 0.75: Adequate control of asthma From 0.75 to 1.50: Partially controlled asthma More than 1.50: Inadequate asthma control
12 months
Secondary Visual Analogue Scale (VAS) Visual Analogue Scale in which the subject has to indicate in a straight line of 10 cm how he/she feels regarding to his allergy symptoms. Being left side "0 = very bad" and right side "10 = very well".
VAS scale will also be completed by the investigator answering how he/she thinks that the patient feels.
12 months
Secondary Consumption of health resources For each patient, the number of times that due to allergy symptoms has done the following will be counted:
have visited the family doctor
have made an unscheduled visit to the specialist
has gone to the emergency room
has been hospitalized
have needed to contact the doctor by phone
12 months
Secondary Safety parameters Global rate and severity of AE per administration and per subject 12 months
Secondary Number of Local Adverse Reactions Local adverse reactions are those that appear at the site of the administration. They are classified into: Immediate (it appears during the first 30 minutes from the administration of investigational product) and Late (it appears after the first 30 minutes from the administration of investigational product) 12 months
Secondary Number of Systemic Adverse Reactions Systemic adverse reactions are those that appear in other parts of the body other than the site of administration.Their severity will be classified following the indications proposed by the World Allergy Organization (WAO) in 2010. 12 months
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT02911688 - Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure Phase 2
Active, not recruiting NCT01776177 - The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy N/A
Completed NCT00485576 - Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma Phase 2
Completed NCT00736801 - Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma N/A
Completed NCT00515775 - Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children N/A
Completed NCT04259164 - Anti-inflammatory Effects Glycopyrronium Phase 3
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Completed NCT01699594 - Change in Airway Responsiveness After Allergen Exposure N/A
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00999466 - The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen Phase 2
Completed NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma Phase 2
Completed NCT00492076 - Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma Phase 4
Completed NCT00829179 - Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma Phase 3
Completed NCT00490425 - Prevention of Asthma and Allergy by Probiotic Lactobacillus GG Phase 4
Recruiting NCT04542902 - Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma N/A
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Active, not recruiting NCT05186025 - Tyrosine Allergoid Paediatric and Adult Study
Withdrawn NCT03307278 - House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance N/A
Enrolling by invitation NCT06151938 - Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis